Newlon Claire, Asaki S Yukiko, Pilcher Thomas A, Ou Zhining, Etheridge Susan P, Niu Mary C
Department of Pediatrics, Division of Pediatric Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, Utah, USA.
Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, Utah, USA.
J Cardiovasc Electrophysiol. 2022 Nov;33(11):2344-2350. doi: 10.1111/jce.15667. Epub 2022 Sep 10.
The safety and utility of the Advisor™ High-Density Grid mapping catheter (HDGC) in children and congenital heart disease (CHD) patients are not well described.
A single-center retrospective cohort study of pediatric and CHD patients undergoing electrophysiology study and ablation to determine the effect of HDGC use on outcomes including complications, fluoroscopy use, procedure duration, acute ablation success, and arrhythmia recurrence.
HDGC was used in 74/261 (28.3%) cases. HDGC subjects differed by median age (17 vs. 13 years; p < 0.001), weight (68 vs. 50 kg; p < 0.001), and prevalence of significant CHD (42% vs. 3%; p < 0.001). Arrhythmia substrates were dissimilar: HGDC cases had higher frequencies of intra-atrial re-entrant tachycardia (25.7% vs. 0.5%), atrial flutter (8.1% vs. 1.1%), ectopic atrial tachycardia (13.5% vs. 3.7%), and premature ventricular contractions (9.5% vs. 0.5%), and lower incidences of atrioventricular re-entrant tachycardia (16.2% vs. 46.1%). Complications were rare (n = 5, 1.9%) with no significant difference between groups (p = 1.00). Procedure duration-but not fluoroscopy exposure-was significantly longer in HDGC cases (median 256 vs. 216 min, p < 0.001). Acute success was lower (93.2% vs. 99.4%; p = 0.01) and recurrences higher (13.2% vs. 3.8%; p = 0.016) in HDGC compared to non-HDGC cases.
HDGC use in children and CHD patients is safe and not associated with higher complication rates. The lower acute success and higher recurrence rates in HDGC cases likely reflect a bias toward HDGC use in more complex arrhythmia substrates rather than less favorable ablation outcomes.
Advisor™高密度标测导管(HDGC)在儿童和先天性心脏病(CHD)患者中的安全性和实用性尚未得到充分描述。
一项针对接受电生理研究和消融治疗的儿科及CHD患者的单中心回顾性队列研究,以确定使用HDGC对包括并发症、透视使用情况、手术时长、急性消融成功率和心律失常复发等结果的影响。
74/261(28.3%)例患者使用了HDGC。使用HDGC的患者在年龄中位数(17岁对13岁;p<0.001)、体重(68千克对50千克;p<0.001)以及严重CHD患病率(42%对3%;p<0.001)方面存在差异。心律失常基质不同:使用HDGC的病例中房内折返性心动过速(25.7%对0.5%)、心房扑动(8.1%对1.1%)、异位房性心动过速(13.5%对3.7%)和室性早搏(9.5%对0.5%)的发生率较高,而房室折返性心动过速的发生率较低(16.2%对46.1%)。并发症罕见(n = 5,1.9%),两组之间无显著差异(p = 1.00)。使用HDGC的病例手术时长显著更长(中位数256分钟对216分钟,p<0.001),但透视暴露时间无显著差异。与未使用HDGC的病例相比,使用HDGC的病例急性成功率较低(93.2%对99.4%;p = 0.01),复发率较高(13.2%对3.8%;p = 0.016)。
在儿童和CHD患者中使用HDGC是安全的,且与更高的并发症发生率无关。使用HDGC的病例中较低的急性成功率和较高的复发率可能反映出在更复杂的心律失常基质中倾向于使用HDGC,而非消融结果不佳。